The Cancer Letter

ACS CAN wages state-by-state battle to expand access to biomarker testing

ACS CAN wages state-by-state battle to expand access to biomarker testing

With growing evidence that molecular characterization of a tumor helps predict a patient’s prognosis and response to specific treatments, biomarker testing has been required or recommended for more than half of the 62 oncology drugs introduced over the past five years. However, health insurance policies don’t always cover tests, thus denying their clients access to precision medicine.
To make clinical trials equitable, cancer groups evaluate restrictive eligibility criteria
Guest EditorialHealth Equity

To make clinical trials equitable, cancer groups evaluate restrictive eligibility criteria

Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).